Background: The pathogenesis of severe dengue disease involves immune components as biomarkers. The mechanism by which some dengue virus (DENV)-infected individuals progress to severe disease is poorly understood. Most studies on the pathogenesis of severe dengue disease focus on the process of antibody-dependent enhancement (ADE) as a primary risk factor. With the circulation of Zika virus (ZIKV) in DENV-endemic areas, many people infected by ZIKV were likely exposed to DENV. The influence of such exposure on Zika disease outcomes remains unknown. Methods: We investigated whether patients previously exposed to DENV exhibited higher viremia when exposed to a subsequent, heterologous dengue or Zika infection than those patients not previously exposed to dengue. We measured viral loads and cytokine profile during patients' acute infections. Results: Neither dengue nor Zika viremia was higher in patients with prior DENV infection, although the power to detect such a difference was only adequate in the ZIKV analysis. Of the 10 cytokines measured, only 1 significant difference was detected: Levels of interleukin 1β (IL-1β) were lower in dengue-infected patients who had experienced a previous dengue infection than patients infected with dengue for the first time. However, power to detect differences between groups was low. In Zika-infected patients, levels of IL-1β showed a significant, positive correlation with viral load. Conclusions: No signs of ADE were observed in vivo in patients with acute ZIKV infection who had prior exposure to DENV.
Background: The pathogenesis of severe dengue disease involves immune components as biomarkers. The mechanism by which some dengue virus (DENV)-infected individuals progress to severe disease is poorly understood. Most studies on the pathogenesis of severe dengue disease focus on the process of antibody-dependent enhancement (ADE) as a primary risk factor. With the circulation of Zika virus (ZIKV) in DENV-endemic areas, many people infected by ZIKV were likely exposed to DENV. The influence of such exposure on Zika disease outcomes remains unknown. Methods: We investigated whether patients previously exposed to DENV exhibited higher viremia when exposed to a subsequent, heterologous dengue or Zika infection than those patients not previously exposed to dengue. We measured viral loads and cytokine profile during patients' acute infections. Results: Neither dengue nor Zika viremia was higher in patients with prior DENVinfection, although the power to detect such a difference was only adequate in the ZIKV analysis. Of the 10 cytokines measured, only 1 significant difference was detected: Levels of interleukin 1β (IL-1β) were lower in dengue-infectedpatients who had experienced a previous dengue infection than patients infected with dengue for the first time. However, power to detect differences between groups was low. In Zika-infectedpatients, levels of IL-1β showed a significant, positive correlation with viral load. Conclusions: No signs of ADE were observed in vivo in patients with acute ZIKV infection who had prior exposure to DENV.
Authors: Catharina Suharti; Eric C M van Gorp; Tatty E Setiati; Wil M V Dolmans; Robert J Djokomoeljanto; C Erik Hack; Cate Hugo ten; Jos W M van der Meer Journal: Thromb Haemost Date: 2002-01 Impact factor: 5.249
Authors: D Hober; L Poli; B Roblin; P Gestas; E Chungue; G Granic; P Imbert; J L Pecarere; R Vergez-Pascal; P Wattre Journal: Am J Trop Med Hyg Date: 1993-03 Impact factor: 2.345
Authors: Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Amanda J Panella; Jason O Velez; Amy J Lambert; Grant L Campbell Journal: Emerg Infect Dis Date: 2007-05 Impact factor: 6.883
Authors: Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Jason O Velez; Amy J Lambert; Alison J Johnson; Stephanie M Stanfield; Mark R Duffy Journal: Emerg Infect Dis Date: 2008-08 Impact factor: 6.883
Authors: Freddy Perez; Anthony Llau; Gamaliel Gutierrez; Haroldo Bezerra; Giovanini Coelho; Steven Ault; Sulamita Brandao Barbiratto; Marcelo Carballo de Resende; Lizbeth Cerezo; Giovanni Luz Kleber; Oscar Pacheco; Octavio Lenin Perez; Victor Picos; Diana P Rojas; Joao Bosco Siqueira; Marco Fidel Suarez; Eva Harris; Luis Gerardo Castellanos; Carlos Espinal; Jose Luis San Martin Journal: Trop Med Int Health Date: 2019-01-28 Impact factor: 2.622
Authors: Nicholas J Barrows; Rafael K Campos; Kuo-Chieh Liao; K Reddisiva Prasanth; Ruben Soto-Acosta; Shih-Chia Yeh; Geraldine Schott-Lerner; Julien Pompon; October M Sessions; Shelton S Bradrick; Mariano A Garcia-Blanco Journal: Chem Rev Date: 2018-04-13 Impact factor: 60.622
Authors: Natalie A Prow; Liang Liu; Mary K McCarthy; Kevin Walters; Raj Kalkeri; Jillian Geiger; Fusataka Koide; Tamara H Cooper; Preethi Eldi; Eri Nakayama; Kerrilyn R Diener; Paul M Howley; John D Hayball; Thomas E Morrison; Andreas Suhrbier Journal: NPJ Vaccines Date: 2020-06-02 Impact factor: 7.344
Authors: Julia A Brown; Gursewak Singh; Joshua A Acklin; Silviana Lee; James E Duehr; Anupa N Chokola; Justin J Frere; Kevin W Hoffman; Gregory A Foster; David Krysztof; Richard Cadagan; Adam R Jacobs; Susan L Stramer; Florian Krammer; Adolfo García-Sastre; Jean K Lim Journal: Immunity Date: 2019-02-05 Impact factor: 31.745
Authors: Leah C Katzelnick; César Narvaez; Sonia Arguello; Brenda Lopez Mercado; Damaris Collado; Oscarlett Ampie; Douglas Elizondo; Tatiana Miranda; Fausto Bustos Carillo; Juan Carlos Mercado; Krista Latta; Amy Schiller; Bruno Segovia-Chumbez; Sergio Ojeda; Nery Sanchez; Miguel Plazaola; Josefina Coloma; M Elizabeth Halloran; Lakshmanane Premkumar; Aubree Gordon; Federico Narvaez; Aravinda M de Silva; Guillermina Kuan; Angel Balmaseda; Eva Harris Journal: Science Date: 2020-08-28 Impact factor: 47.728